| Autor: |
Kubinski, Mareike, Beicht, Jana, Zdora, Isabel, Biermann, Jeannine, Puff, Christina, Gerlach, Thomas, Tscherne, Alina, Baumgärtner, Wolfgang, Osterhaus, Albert D. M. E., Sutter, Gerd, Prajeeth, Chittappen Kandiyil, Rimmelzwaan, Guus F. |
| Předmět: |
|
| Zdroj: |
Frontiers in Immunology; 2023, p1-15, 15p |
| Abstrakt: |
Introduction: Tick-borne encephalitis virus (TBEV) is an important human pathogen that can cause a serious disease involving the central nervous system (tick-borne encephalitis, TBE). Although approved inactivated vaccines are available, the number of TBE cases is rising, and breakthrough infections in fully vaccinated subjects have been reported in recent years. Methods: In the present study, we generated and characterized a recombinant Modified Vaccinia virus Ankara (MVA) for the delivery of the pre-membrane (prM) and envelope (E) proteins of TBEV (MVA-prME). Results: MVA-prME was tested in mice in comparison with a licensed vaccine FSME-IMMUN® and proved to be highly immunogenic and afforded full protection against challenge infection with TBEV. Discussion: Our data indicate that MVA-prME holds promise as an improved next-generation vaccine for the prevention of TBE. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
